LB30057 Inhibits Platelet Aggregation and Vascular Relaxation Induced by Thrombin

  • Jung, Byoung-In (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Kang, a-Kyu-Tae (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Bae, Ok-Nam (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Lee, Moo-Yeol (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Chung, Seung-Min (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University) ;
  • Lee, Sang-Koo (Biotech Research Institute, LG Chemical) ;
  • Kim, In-Chul (Biotech Research Institute, LG Chemical) ;
  • Chung, Jin-Ho (Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University)
  • Published : 2002.12.01

Abstract

Previous study showed that an amidrazonophenylalanine derivative, LB30057, which has high water solubility, inhibited the catalytic activity of thrombin potently by interaction with the active site of thrombin. In the current investigation, we examined whether LB30057 inhibited platelet aggregation and vascular relaxation induced by thrombin. Treatment with LB30057 to plateletrich plasma (PRP) isolated from human blood resulted in a concentration-dependent inhibition of thrombin-induced aggregation. Values for $IC_{50}$ and $IC_{100}$ were $54{\pm}4$ nM and $96{\pm}3$ nM, respectively. This inhibition was agonist (thrombin) specific, since $IC_{50}$ values for collagen and ADP were \much greater than those for thrombin. In addition, concentration-dependent inhibitory effects were observed on the serotonin secretion induced by thrombin in PRP. Consistent with these findings, thrombin-induced increase in cytosolic calcium levels was inhibited in a concentration-dependent manner. When LB30057 was treated with aortic rings isolated from rats, LB30057 resulted in a concentration-dependent inhibition of thrombin-induced vascular relaxation. All these results suggest that LB30057 is a potent inhibitor of platelet aggregation and blood vessel relaxation induced by thrombin.

Keywords

References

  1. Authi, K. S., Localization of the [$^{32}P$]IP3 binding site on human platelet intracellular membranes isolated by high-voltage free- flowelectrophoresis. FEBS Lett., 298, 173-176(1992) https://doi.org/10.1016/0014-5793(92)80049-M
  2. Becker, R. C., Thrombin antagonists and antiplatelet agents. Am. J. Cardiol., 69, 39A-51A (1992) https://doi.org/10.1016/0002-9149(92)91170-9
  3. Eidt, J. F., Allison, P., Noble, S., Ashton, J., Golino, P., McNatt, J., Buja, L. M. and Willerson, J. T., Thrombin is an important mediatorof platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest., 84, 18-27 (1989) https://doi.org/10.1172/JCI114138
  4. Gustafsson, D., Antonsson, T., Bylund, R., Eriksson, U., Gyzander, E., Nilsson, I., Elg, M., Mattsson, C., Deinum, J., Pehrsson, S., Karlsson, O., Nilsson, A. and Sorensen, H., Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost., 79, 110-118 (1998) https://doi.org/10.1055/s-0037-1614245
  5. Hirsh, J., Heparin. N. Engl. J. Med., 324, 1565-1574(1991) https://doi.org/10.1056/NEJM199105303242206
  6. Hughes, P. E. and Pfaff, M., Integrin affinity modulation. Trends Cell Biol., 8, 359-364 (1998) https://doi.org/10.1016/S0962-8924(98)01339-7
  7. Hursting, M. J., Alford, K. L., Becker, J. C., Brooks, R L., Joffrion, J. L., Knappenberger, G. D., Kogan, P. W., Kogan, T. P., McKinney, A. A and Schwarz, R. P., Jr., Novastan(brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemost., 23, 503-516 (1997) https://doi.org/10.1055/s-2007-996128
  8. Kelton, J. G., Sheridan, D., Santos, A, Smith, J., Steeves, K., Smith, C., Brown, C. and Murphy, W G., Heparin-induced thrombocytopenia: laboratory studies. Blood, 72, 925-930 (1988)
  9. Lee, S. K., Lee, J. Y., Lee, M. Y., Chung,S. M. and Chung, J. H., Advantagesof calciumgreen-1 over other fluorescent dyes in measuring cytosolic calcium in platelets. Anal. Biochem, 273, 186-191 (1999) https://doi.org/10.1006/abio.1999.4212
  10. Matsuo, T., Koide, M. and Kario, K., Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin. Thromb. Hemost., 23, 517-522 (1997) https://doi.org/10.1055/s-2007-996129
  11. Oh, Y. S., Yun, M., Hwang, S. Y., Hong, S., Shin, Y., Lee, K., Yoon, K. H., Yoo, Y. J., Kim, D. S., Lee, S. H., Lee, Y. H., Park, H. D., Lee, C. H., Lee, S. K. and Kim, S., Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorg. Med. Chem. Lett., 8, 631-634 (1998) https://doi.org/10.1016/S0960-894X(98)00079-1
  12. Ripka, W. C., New thrombin inhibitors in cardiovascular disease. Curr. Opin. Chem. Biol., 1, 242-253 (1997) https://doi.org/10.1016/S1367-5931(97)80016-6
  13. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362, 801-809 (1993) https://doi.org/10.1038/362801a0
  14. Turpie, A. G., Weitz, J. I. and Hirsh, J., Advances in antithrombotic therapy: novel agents. Thromb. Haemost., 74, 565-571 (1995)
  15. Van Nueten, J. M., Leysen, J. E., de Clerck, F. and Vanhoutte, P.M., Serotonergic receptor subtypes andvascular reactivity. J. Cardiovasc. Pharmacol., 6 Suppl4, S564-S574(1984) https://doi.org/10.1097/00005344-198406004-00003
  16. Vanhoutte, PM., 5-hydroxytryptamine and vascular disease. Fed. Proc., 42, 233-237 (1983)
  17. Vanhoutte, P. M. and Houston, D. S., Platelets, endothelium, and vasospasm. Circulation, 72, 728-734 (1985) https://doi.org/10.1161/01.CIR.72.4.728
  18. Weitz, J. I., Biological rationale for the therapeutic role of specific antithrombins. Caron. Artery Dis,. 7, 409-419 (1996) https://doi.org/10.1097/00019501-199606000-00003
  19. Zimmerman, G. A., Elstad, M. R., Lorant, D. E., Mcintyre, T M., Prescott, S. M., Topham, M. K., Weyrich, A. S. and Whatley, R. E., Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv. Exp. Med. Biol., 416, 297-304 (1996)